MGM RESORTS INTERNATIONAL REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

— Consolidated net revenues increased 2% year over year — MGM China achieved both record 3Q Segment Adjusted EBITDAR and market share of 15.5% — BetMGM North American venture reported strong revenue and EBITDA growth in 3Q25, raising its guidance for FY2025 and announcing cash distribution to MGM Resorts by year-end 2025 — Announced sale […]

SERVICE CORPORATION INTERNATIONAL ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS, CONFIRMS 2025 EARNINGS MIDPOINT AND RAISES 2025 CASH FLOW GUIDANCE

Conference call on Thursday, October30, 2025, at 8:00 a.m. Central Time. HOUSTON, Oct. 29, 2025 Service Corporation International (NYSE: SCI), the largest provider of deathcare products and services in North America, today reported results for the third quarter of 2025. ThirdQuarter Highlights: — Revenue grew $44.1 million, or 4.4%, over the third quarter of 2024

Flotek’s ‘XSPCT ™’ Custody Transfer Unit Becomes the First Optical Spectrometer to Meet GPA 2172 Standard

Flotek Industries, Inc. (“Flotek”) (NYSE: FTK) has achieved a historic milestone in natural gas measurement. Its XSPCT optical spectrometer is the first optical instrument to achieve the stringent reproducibility and repeatability requirements of GPA 2172 (API 14.5), the oil and gas industry standard for accurate custody transfer. The XSPCT measurement unit is designed to enable

PREFORMED LINE PRODUCTS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

Preformed Line Products Company (NASDAQ: PLPC) today reported financial results for its third quarter of 2025. https://mma.prnewswire.com/media/1604008/Preformed_Line_Products_New_Logo.jpg Q3 2025 highlights compared to same quarter last year: — Net sales growth of 21% — Previously announced U.S. Pension Plan termination successfully completed in Q3, resulting in a non-cash pre-tax charge of $11.7 million — Fully diluted

First US Bancshares, Inc. Reports Third Quarter 2025 Results

Third Quarter Highlights: First US Bancshares, Inc. (Nasdaq: FUSB) (the “Company”), the parent company of First US Bank (the “Bank”), today reported net income of $1.9 million, or $0.32 per diluted share, for the quarter ended September30, 2025 (“3Q2025”), compared to $0.2 million, or $0.03 per diluted share, for the quarter ended June 30, 2025

Canadian Investment Regulatory Organization Trading Halt – BYD

The following issues have been halted by CIRO: Company: Boyd Group Services Inc. TSX Symbol: BYD All Issues: Yes Reason: Pending News Halt Time (ET): 4:01 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair

First Commerce Bancorp, Inc. Reports Third Quarter and Year-to-Date 2025 Results

(PinkSheets:CMRB),(Pinksheets:CMRB), LAKEWOOD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) — First Commerce Bancorp, Inc. (the “Company”), (OTC: CMRB), the holding company for First Commerce Bank (the “Bank”), today reported net income of $2.1 million and $5.1 million for the three and nine months ending September 30, 2025, respectively, as compared to $1.1 million and $3.4 million

Aecon reports third quarter 2025 results

(TSX:ARE), TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) today reported results for the third quarter of 2025. “Aecon achieved 20% revenue growth, added to record backlog, and is strategically positioned to support the delivery of critical infrastructure projects in nuclear, energy generation, storage, distribution and transmission,

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

(NYSE:EBS), Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

(NasdaqGM:WVE), Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date Activin E reduction in lowest dose cohort of INLIGHT was sustained through 6 months,

Scroll to Top